Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Extensive Stage Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- June 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of Southern California, Norris Comprehensive Cancer Center · Los Angeles, CA
Illinois · 1
- University of Illinois Chicago · Chicago, IL
Michigan · 1
- Trinity Health Saint Joseph Mercy Ann Arbor · Ann Arbor, MI
South Dakota · 1
- Avera Cancer Institute · Sioux Falls, SD
Texas · 1
- University of Texas MD Anderson Cancer Center · Houston, TX
Washington · 1
- Swedish Cancer Institute · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.